| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1755* | 2021 |
| Effect of hydroxychloroquine in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 383 (21), 2030-2040, 2020 | 1461 | 2020 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 912 | 2022 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 765 | 2021 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 725 | 2021 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 673 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 673 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 372* | 2021 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 317 | 2021 |
| Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients AH Mohsen, PJ Easterbrook, C Taylor, B Portmann, R Kulasegaram, ... Gut 52 (7), 1035-1040, 2003 | 317 | 2003 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 286 | 2021 |
| Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study RK Gupta, EM Harrison, A Ho, AB Docherty, SR Knight, M van Smeden, ... The Lancet Respiratory Medicine 9 (4), 349-359, 2021 | 208 | 2021 |
| Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting J Schmid, FC Odds, MJ Wiselka, KG Nicholson, DR Soll Journal of Clinical Microbiology 30 (4), 935-941, 1992 | 180 | 1992 |
| Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial GE Thwaites, M Scarborough, A Szubert, E Nsutebu, R Tilley, J Greig, ... The Lancet 391 (10121), 668-678, 2018 | 177 | 2018 |
| Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the … CI Bloom, TM Drake, AB Docherty, BJ Lipworth, SL Johnston, ... The Lancet Respiratory Medicine 9 (7), 699-711, 2021 | 164 | 2021 |
| Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study CA Martin, DR Jenkins, JS Minhas, LJ Gray, J Tang, C Williams, S Sze, ... EClinicalMedicine 25, 2020 | 156 | 2020 |
| Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study TM Drake, AM Riad, CJ Fairfield, C Egan, SR Knight, R Pius, ... The Lancet 398 (10296), 223-237, 2021 | 144 | 2021 |
| A prenylated dsRNA sensor protects against severe COVID-19 A Wickenhagen, E Sugrue, S Lytras, S Kuchi, M Noerenberg, ML Turnbull, ... Science 374 (6567), eabj3624, 2021 | 142 | 2021 |
| Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a … APS Munro, S Feng, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, ... The Lancet Infectious Diseases 22 (8), 1131-1141, 2022 | 137 | 2022 |
| Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma KG Nicholson, JS Nguyen-Van-Tam, HA Ala'eldin, MJ Wiselka, J Leese, ... The Lancet 351 (9099), 326-331, 1998 | 127 | 1998 |
